In summary, we identified the oncogenetic function of MTDH in MM and pointed out that Bortezomib was a therapeutic reagent for MTDH through inhibiting MMSET/NFκB/MYC transcription (Figure 6D). This evidence concerns the gene MTDH and Miyoshi myopathy.